Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients

Overview of attention for article published in BMJ Open Gastroenterology, July 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 389)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 15 news stories from 12 outlets.

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail…

GlobeNewswire 2023-11-28 FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail…

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 11 additional news stories.